MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency
- PMID: 29736023
- DOI: 10.1038/s41591-018-0015-9
MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency
Abstract
Genetic defects underlying the melanocortin-4 receptor (MC4R) signaling pathway lead to severe obesity. Three severely obese LEPR-deficient individuals were administered the MC4R agonist setmelanotide, resulting in substantial and durable reductions in hyperphagia and body weight over an observation period of 45-61 weeks. Compared to formerly developed and tested MC4R agonists, setmelanotide has the unique capability of activating nuclear factor of activated T cell (NFAT) signaling and restoring function of this signaling pathway for selected MC4R variants. Our data demonstrate the potency of setmelanotide in treatment of individuals with diverse MC4R-related pathway deficiencies.
Similar articles
-
Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials.Lancet Diabetes Endocrinol. 2020 Dec;8(12):960-970. doi: 10.1016/S2213-8587(20)30364-8. Epub 2020 Oct 30. Lancet Diabetes Endocrinol. 2020. PMID: 33137293 Clinical Trial.
-
Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency.Mol Metab. 2017 Oct;6(10):1321-1329. doi: 10.1016/j.molmet.2017.06.015. Epub 2017 Jul 8. Mol Metab. 2017. PMID: 29031731 Free PMC article. Clinical Trial.
-
Structural analysis of setmelanotide binding to MC4R variants in comparison to wild-type receptor.Life Sci. 2022 Oct 15;307:120857. doi: 10.1016/j.lfs.2022.120857. Epub 2022 Aug 2. Life Sci. 2022. PMID: 35931197
-
Setmelanotide: First Approval.Drugs. 2021 Feb;81(3):397-403. doi: 10.1007/s40265-021-01470-9. Drugs. 2021. PMID: 33638809 Review.
-
Melanocortin-4 Receptor Signalling: Importance for Weight Regulation and Obesity Treatment.Trends Mol Med. 2019 Feb;25(2):136-148. doi: 10.1016/j.molmed.2018.12.002. Epub 2019 Jan 11. Trends Mol Med. 2019. PMID: 30642682 Review.
Cited by
-
Immunogenetic Aspects of Sarcopenic Obesity.Genes (Basel). 2024 Feb 5;15(2):206. doi: 10.3390/genes15020206. Genes (Basel). 2024. PMID: 38397196 Free PMC article. Review.
-
Ascorbate-induced oxidative stress mediates TRP channel activation and cytotoxicity in human etoposide-sensitive and -resistant retinoblastoma cells.Lab Invest. 2021 Jan;101(1):70-88. doi: 10.1038/s41374-020-00485-2. Epub 2020 Sep 18. Lab Invest. 2021. PMID: 32948812 Free PMC article.
-
Late onset obesity in mice with targeted deletion of potassium inward rectifier Kir7.1 from cells expressing the melanocortin-4 receptor.J Neuroendocrinol. 2019 Jan;31(1):e12670. doi: 10.1111/jne.12670. Epub 2019 Jan 20. J Neuroendocrinol. 2019. PMID: 30561082 Free PMC article.
-
A Setmelanotide-like Effect at MC4R Is Achieved by MC4R Dimer Separation.Biomolecules. 2022 Aug 15;12(8):1119. doi: 10.3390/biom12081119. Biomolecules. 2022. PMID: 36009013 Free PMC article.
-
The Narrative of a Patient with Leptin Receptor Deficiency: Personalized Medicine for a Rare Genetic Obesity Disorder.Obes Facts. 2023;16(5):514-518. doi: 10.1159/000531529. Epub 2023 Jul 1. Obes Facts. 2023. PMID: 37393902 Free PMC article.
References
-
- Farooqi, I. S. & O’Rahilly, S. J. Endocrinol. 223, T63–T70 (2014). - DOI
-
- Krishna, R. et al. Clin. Pharmacol. Ther. 86, 659–666 (2009). - DOI
-
- Farooqi, I. S. et al. N. Engl. J. Med. 341, 879–884 (1999). - DOI
-
- Clément, K. et al. Nature 392, 398–401 (1998). - DOI
-
- Jackson, V. M., Price, D. A. & Carpino, P. A. Expert Opin. Investig. Drugs 23, 1055–1066 (2014). - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous